NO933327L - Farmasoeytisk kombinasjon for behandling av prostatisk hyperplasi, inneholdende en 5alpha-reduktaseinhibitor og et antiandrogen - Google Patents

Farmasoeytisk kombinasjon for behandling av prostatisk hyperplasi, inneholdende en 5alpha-reduktaseinhibitor og et antiandrogen

Info

Publication number
NO933327L
NO933327L NO933327A NO933327A NO933327L NO 933327 L NO933327 L NO 933327L NO 933327 A NO933327 A NO 933327A NO 933327 A NO933327 A NO 933327A NO 933327 L NO933327 L NO 933327L
Authority
NO
Norway
Prior art keywords
antiandrogen
treatment
reductase inhibitor
pharmaceutical combination
prostatic hyperplasia
Prior art date
Application number
NO933327A
Other languages
English (en)
Other versions
NO305635B1 (no
NO933327D0 (no
Inventor
Glenn J Gormley
Elizabeth Stoner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO933327(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO933327D0 publication Critical patent/NO933327D0/no
Publication of NO933327L publication Critical patent/NO933327L/no
Publication of NO305635B1 publication Critical patent/NO305635B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO933327A 1991-03-20 1993-09-17 Farmas°ytisk preparat for behandling av prostatisk hyperplasi inneholdende finasterid og terazosin NO305635B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67251191A 1991-03-20 1991-03-20
US84615392A 1992-03-11 1992-03-11
PCT/US1992/002258 WO1992016213A1 (en) 1991-03-20 1992-03-19 Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen

Publications (3)

Publication Number Publication Date
NO933327D0 NO933327D0 (no) 1993-09-17
NO933327L true NO933327L (no) 1993-11-17
NO305635B1 NO305635B1 (no) 1999-07-05

Family

ID=27100766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933327A NO305635B1 (no) 1991-03-20 1993-09-17 Farmas°ytisk preparat for behandling av prostatisk hyperplasi inneholdende finasterid og terazosin

Country Status (18)

Country Link
US (2) US5753641A (no)
EP (1) EP0576603A1 (no)
JP (1) JPH06506227A (no)
AU (1) AU666846B2 (no)
BG (1) BG61798B1 (no)
CA (1) CA2104793C (no)
CZ (1) CZ292712B6 (no)
HU (1) HUT66273A (no)
IE (1) IE920879A1 (no)
IL (1) IL101243A (no)
NO (1) NO305635B1 (no)
NZ (1) NZ241979A (no)
RO (1) RO113613B1 (no)
RU (1) RU2125879C1 (no)
SG (1) SG80530A1 (no)
SK (1) SK284381B6 (no)
UA (1) UA41305C2 (no)
WO (1) WO1992016213A1 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547687A1 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones
MX9301939A (es) * 1992-04-02 1994-08-31 Smithkline Beecham Corp Composicion farmaceutica que comprende un compuesto inhibidor de 5-ó-reductasa esteroidal.
WO1994009785A2 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
CA2158345A1 (en) * 1993-03-15 1994-09-29 Marvin L. Bayne Cloned human alpha 1c adrenergic receptor
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
GB9603457D0 (no) * 1996-02-19 1996-04-17 Merck & Co Inc
US6096763A (en) * 1995-02-23 2000-08-01 Merck & Co., Inc. α1a adrenergic receptor antagonists
US5952351A (en) * 1995-02-23 1999-09-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US5670643A (en) * 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
WO2000006565A1 (en) 1998-07-30 2000-02-10 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
WO2000025782A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6423719B1 (en) 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2002330031B2 (en) * 2001-09-21 2007-07-05 Merck & Co., Inc. Androstanes as androgen receptor modulators
ES2287474T3 (es) * 2002-04-24 2007-12-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Combinacion farmaceutica para el tratamiento de la hiperplasia prostatica benigna o para la prevencion a la largo plazo de la retencion urinaria aguda.
AU2003294913A1 (en) * 2002-12-23 2004-07-22 Basf Aktiengesellschaft Hydrophobic-hydrophilic compounds for treating metallic surfaces
AU2004256075B2 (en) * 2003-06-30 2008-12-04 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007522087A (ja) * 2003-06-30 2007-08-09 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
CA2530182A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
EP1641761A4 (en) * 2003-06-30 2008-05-14 Merck & Co Inc 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP2099375B1 (en) 2007-01-02 2014-09-24 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
MX2007003949A (es) * 2007-04-02 2009-02-25 World Trade Imp Export Wtie Ag Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos.
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
EP3622910B1 (en) 2008-03-06 2024-07-10 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
GR1006492B (el) * 2008-05-29 2009-07-22 Νικολαος Χρηστου Δημοφιλος Συνεργατικη επαγωγη αποπτωσης προστατικου ιστου-προληψη καρκινου προστατου-νεα πρακτικη περιφερικου ανδρογονικου αποκλεισμου-κατασκευη συμπλοκου δισκιου
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2016004071A1 (en) 2014-06-30 2016-01-07 Procept Biorobotics Corporation Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
CN104203078B (zh) 2012-02-29 2018-04-20 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
CN105431096B (zh) 2013-02-14 2018-07-31 普罗赛普特生物机器人公司 液体消融液体束眼外科手术的方法和装置
EP3024474B1 (en) 2013-07-23 2022-01-05 Serenity Pharmaceuticals LLC Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
EP3024473A1 (en) 2013-07-23 2016-06-01 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
BR112016005036A2 (pt) 2013-09-06 2020-04-07 Procept Biorobotics Corp aparelho para ressecção de tecido guiada por imagem automatizada
CN114224438A (zh) 2014-09-05 2022-03-25 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除
CN104277089A (zh) * 2014-09-30 2015-01-14 湖南科瑞生物科技有限公司 一种雄甾-17β-羧酸的制备方法
WO2016081772A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3980650A (en) * 1972-05-05 1976-09-14 N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia 4-Amino-pyrimidine derivatives
JPS4966691A (no) * 1972-10-30 1974-06-27
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB2007656B (en) * 1977-11-05 1982-05-19 Pfizer Ltd Therapeutic agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
EP0314199B1 (en) * 1984-02-27 1991-09-18 Merck & Co. Inc. 17 beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US4888366A (en) * 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0291245B1 (en) * 1987-05-11 1992-07-22 Ono Pharmaceutical Co., Ltd. Benzoylaminophenoxybutanoic acid derivatives
AU627466B2 (en) * 1988-05-25 1992-08-27 Smithkline Beckman Corporation Aromatic steroid 5-alpha-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
CA2050291C (en) * 1989-03-10 2000-12-19 Fernand Labrie Combination therapy for the treatment of estrogen sensitive diseases
KR920703065A (ko) * 1989-07-07 1992-12-17 원본미기재 안드로겐 관련질병의 치료방법
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
MX9301939A (es) * 1992-04-02 1994-08-31 Smithkline Beecham Corp Composicion farmaceutica que comprende un compuesto inhibidor de 5-ó-reductasa esteroidal.

Also Published As

Publication number Publication date
CA2104793C (en) 2004-06-22
HUT66273A (en) 1994-11-28
CZ193393A3 (en) 1994-08-17
RU2125879C1 (ru) 1999-02-10
NZ241979A (en) 1996-01-26
US6046183A (en) 2000-04-04
BG98113A (bg) 1994-06-30
JPH06506227A (ja) 1994-07-14
AU666846B2 (en) 1996-02-29
EP0576603A1 (en) 1994-01-05
CA2104793A1 (en) 1992-09-21
UA41305C2 (uk) 2001-09-17
IL101243A (en) 1999-12-22
SK284381B6 (sk) 2005-02-04
WO1992016213A1 (en) 1992-10-01
AU1751492A (en) 1992-10-21
NO305635B1 (no) 1999-07-05
NO933327D0 (no) 1993-09-17
HU9302624D0 (en) 1993-12-28
BG61798B1 (bg) 1998-06-30
IL101243A0 (en) 1992-11-15
CZ292712B6 (cs) 2003-12-17
RO113613B1 (ro) 1998-09-30
SG80530A1 (en) 2001-05-22
US5753641A (en) 1998-05-19
IE920879A1 (en) 1992-09-23
SK100693A3 (en) 1994-11-09

Similar Documents

Publication Publication Date Title
NO933327L (no) Farmasoeytisk kombinasjon for behandling av prostatisk hyperplasi, inneholdende en 5alpha-reduktaseinhibitor og et antiandrogen
NO923239D0 (no) Fremgangsmaate til utsendelse og mottagelse av personlige programmer
NO971015L (no) Forbindelser og metoder for behandling av cancer
NO911915D0 (no) Slagloddingslegering og anvendelse av denne.
AU1893492A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
NO932915D0 (no) Mikroporoest krystallinsk silikoaluminofosfat og fremgangsmaate for fremstilling av dette
NO164219C (no) Fremgangsmaate og anlegg for behandling av returnert boreslam.
NO920249L (no) Fartoeyskrog og fremgangsmaate til bygging av dette
NO924704L (no) Medikamenter for behandling av betennelsestilstander og for analgesi
FI920424A (fi) Foerfarande foer anvaendning av metalliseringsanlaeggning och anordning foer utfoerande av foerfarandet
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
NO172838C (no) Fremgangsmaate og anlegg for behandling av avfallsprodukter
NO922819L (no) Reaktor og fremgangsmaate for fremstilling av syntesegass
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO951718D0 (no) Fremgangsmåter og sammensetninger av (+)doksazosin for behandling av godartet hyperplasi og aterosklerose
NO905291L (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer.
NO932912D0 (no) Preparat og fremgangsmaater til generering av ben
NO933021D0 (no) Sonde for mikroboelgeapparat til klinisk og kirurgisk behandling
DK0661981T3 (da) Anvendelse af hyaluronsyre og derivater heraf til forebyggelse mod arteriel restenose
ITTO920023U1 (it) Armadio componibile di semplice, robusta ed economica esecuzione.
NO920546L (no) Fremgangsmaate for flussbehandling og flussvedheftende komponent
NO941245D0 (no) Anordning for desinfeksjon av et sanitæranlegg og sanitærutstyr
NO902288D0 (no) Fremgangsmaate og anordning for aa hindre utlekking av oljeved grunnstoetning av tankskip.
NO911350D0 (no) Utstyr og fremgangsmaate for knusing av boelger.
NO913964L (no) Fremgangsmaate og anlegg for behandling av avfall